Overview
- Injectable GLP-1 drugs including Wegovy, Ozempic and Zepbound will be offered to cash buyers at roughly $300–$350 per month on TrumpRx, with officials saying the average could fall toward $245 over two years.
- Future oral GLP-1 pills are pledged at $149 per month for starter doses if the FDA approves them, with higher-dose tiers priced above that.
- Medicare coverage expands for patients meeting clinical criteria with a $50 monthly out-of-pocket cap targeted for mid-2026, while Medicaid discounts hinge on state adoption.
- Key terms include a January 2026 launch of the government-facilitated direct-to-consumer channel and three years of tariff relief for the companies, as Novo Nordisk and Eli Lilly shares fell after the announcement.
- The pricing push arrives alongside USDA-approved SNAP waivers allowing 12 states to restrict purchases of soda or candy in 2026, a shift that supporters frame as nutrition policy and critics call paternalistic.